<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20091021002618N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-10-14</date_registration>
      <primary_sponsor>Lorestan University of Medical Sciences</primary_sponsor>
      <public_title>Evaluation of the effect of Aromatherapy with Geranium on Anxiety and Labor pain</public_title>
      <acronym></acronym>
      <scientific_title>Evaluation of the Effect of Aromatherapy with Geranium Essence on Anxiety and Labor pain in Nulliparous Women</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-10-07</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>100</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/71548</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Supportive, Randomization description: The sampling method is accessible and based on the study entry criteria. In this way, after obtaining written consent from the samples, people are assigned to 2 intervention and control groups using block random allocation method and blocks of 4. By using this method, it can be ensured that an equal number of participants enter the intervention and control groups in consecutive time intervals. Entry of people into each of the groups is done according to the number of selected blocks and the arrangement inside the block. In order to prevent the possibility of the effect of the aroma spread in the air on the people of the studied groups, the department manager will be requested to place the studied samples in a separate room based on randomization and the same type of intervention received.
For blocks of 4, six modes are considered as follows, and the said blocks will be used approximately 4 times (24 people are allocated each time) so that the final sample size is allocated to two treatment and intervention groups:

1. TTCC 
2. TCTC
3. TCCT
4. CCTT
5. CTCT 
6. CTTC, Blinding description: This research will be double-blind in such a way that neither the researcher responsible for data entry into the software and data analysis nor the researcher (using a nose clip during the intervention) will be aware of the allocation of patients to the experimental or control group; Also, due to the possibility of the release of essential oil molecules in the environment, the release of pleasant odors (scented sprays) and sometimes the windows being open, we place the patients in separate LDR rooms and avoid opening the windows during the intervention; We also ask the hospital services to postpone the cleaning of the room, which is done using detergent solutions and may have an unpleasant smell, to before or after the intervention. The data will be collected by the researcher and the research assistant.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Anxiety and labor pain.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In the aromatherapy group, 2 drops (0.13 cc) of geranium essential oil are soaked in gauze and attached to the collar of the samples, and the administration will be repeated every 20 minutes. The intensity of anxiety will be measured in dilatations of 4 to 5 and 8 to 10 cm and the intensity of pain in dilatations of 4 to 5, 6 to 7 and 8 to 10 cm. Intervention 2: Control group: In the control group, 2 drops (0.13 cc) of distilled water are soaked in gauze and attached to the collar of the samples, and the administration will be repeated every 20 minutes. The intensity of anxiety will be measured in dilatations of 4 to 5 and 8 to 10 cm and the intensity of pain in dilatations of 4 to 5, 6 to 7 and 8 to 10 cm.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Soheila Pirdade Biranvand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kamalvand</address>
        <city>Khorramabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6813833946</zip>
        <telephone>+98 66 3330 2033</telephone>
        <email>kimia_n72@gmail.com</email>
        <affiliation>Lorestan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Soheila Pirdade Biranvand</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kamalvand</address>
        <city>Khorramabad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6813833946</zip>
        <telephone>+98 66 3330 2033</telephone>
        <email>kimia_n72@gmail.com</email>
        <affiliation>Lorestan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Iranian race and being a firstborn
Single pregnancy with age 37 to 42 weeks
Mother's age is 18-35 years
Dilatation 4-5 cm at the beginning of labor
Having at least 2-3 spontaneous uterine contractions lasting 40-45 seconds within 10 minutes
The regularity of the fetal heartbeat with a number of 110-160 beats per minute
The mother's vital signs are normal
The number of fetal movements is normal according to the mother's report
Body mass index 20-30 kg/m2
Height more than 145 cm
The estimated weight of the fetus is 2500-4000 grams
The fit of the fetal head with the mother's pelvis based on clinical examination
Proportion of uterine height with gestational age in clinical examination</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>35 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Fetal distress or disruption of labor progress
Existence of medical and midwifery problems in the current pregnancy
Incidence of sensitivity to geranium essential oil in a person during the study
The presence of olfactory disorders, allergies or previous unpleasant experiences with certain scents
The use of painkillers or anti-anxiety drugs at least 3 hours before the intervention
Addiction to tobacco, drugs and alcohol and the need to receive them
The existence of any obstacle to perform natural childbirth
The need to strengthen labor with oxytocin or other methods
The need for an emergency caesarean section
The need to use other medicinal and non-medicinal pain reduction methods
Facing an important and unfortunate incident during the last week</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In the aromatherapy group, 2 drops (0.13 cc) of geranium essential oil are soaked in gauze and attached to the collar of the samples, and the administration will be repeated every 20 minutes. The intensity of anxiety will be measured in dilatations of 4 to 5 and 8 to 10 cm and the intensity of pain in dilatations of 4 to 5, 6 to 7 and 8 to 10 cm.</i_keyword>
      <i_keyword>Control group: In the control group, 2 drops (0.13 cc) of distilled water are soaked in gauze and attached to the collar of the samples, and the administration will be repeated every 20 minutes. The intensity of anxiety will be measured in dilatations of 4 to 5 and 8 to 10 cm and the intensity of pain in dilatations of 4 to 5, 6 to 7 and 8 to 10 cm.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Anxiety intensity score in Spielberger Anxiety Questionnaire. Timepoint: The intensity of anxiety will be measured before aromatherapy and in dilations of 4 to 5 and 8 to 10 cm. Method of measurement: Spielberger anxiety questionnaire.</prim_outcome>
      <prim_outcome>Labor pain intensity score on visual analog grade scale. Timepoint: Pain intensity will be measured before aromatherapy and at 4 to 5, 6 to 7 and 8 to 10 cm dilatations. Method of measurement: Visual analog degree scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Lorestan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-05-24</approval_date>
        <contact_name>Ethics Committee of Lorestan University of Medical Sciences</contact_name>
        <contact_address>Headquarters of Lorestan University of Medical Sciences, Anoushirvan Rezaei Square, Moalem St. Khorram abad Lorestan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
